TeraCyte Analytics (TeraCyte.AI)

CEO- Yoav Nissan-Cohen

CATEGORY: Biotech

SESSIONS

- AI Meets Pharma
- Frontiers in Biochip and Bio-Devices

Briefly describe the company's technology or therapeutic focus; the market opportunity, progress made to date, key partnerships or joint ventures, investment to date; and management strengths.

TeraCyte pioneers Temporal Cytometry™, a high-throughput platform that captures dynamic single-cell data at scale to power predictive AI. With successful projects in biopharma, our first system sale, and a partnership with SHEBA, we are reshaping biological AI. Our interdisciplinary team, combining expertise in silicon fabrication, machine learning and biology, drives synergy and innovation

Core Technology: What is the technology, its uniqueness, and its value proposition?

Temporal Cytometry™ platform leverages advanced imaging, proprietary silicon chips, and dedicated AI powered software for high-throughput, time-resolved single-cell analysis. Unlike static assays, it continuously tracks cellular dynamics, enabling deep insights into cell behavior and system dynamics. This allows precise measurement of millions of cells, generating unparalleled datasets in scale, standardization and granularity.

Product Profile/Pipeline Briefly describe the company's product/pipeline, status, and market potential. Discuss milestones, potential collaborations, and partnerships.

Temporal Cytometry™ enables clinical immunology and bioproduction optimization. We've collaborated with industry leaders and top academic institutions providing deep insights into mode of action, compound uptake, and yield. We also sold a system to the Technion, with 3 additional deployments expected in Q3 2025. Our target market includes biotech, CDMOs, and pharma, with 2025 milestones of expanding commercial sales, and validating AI-driven clinical immunology models.

Business Strategy Briefly describe how the company will apply its core technology, generate short-term and long-term revenues.

Our short-term strategy drives revenue through research services and system sales to academia and industry, with recurring ARR from disposable chips and AI models. Based on existing sales of several commercial projects, including returning customers, and a sale of a system. Our long-term strategy is developing proprietary AI models, partnering with SHEBA for clinical immunology and Lonza for bioproduction, expanding into high-value applications in drug development and bioprocess optimization.

What's Next? R&D, Preclinical / Clinicals, Organizational Plans, Financial Plans

We are finalizing our beta system for Q2 2025 deployment while advancing AI model development. Key collaborations, including SHEBA (clinical immunology) and Lonza (bioproduction stability), drive technology validation. Organizationally, we are scaling R&D and Marketing & Sales to expedite commercialization. Financially, we aim to raise capital in late 2025 to support growth, expand system sales, and accelerate AI-driven applications.